Citations

Clear

9 citation(s) found for "Liu, Mei".

Quality of life and care experiences in a US multi-institutional neuroendocrine tumor cohort
O’Rorke, Michael A, DeCook, Rhonda, McDowell, Bradley D. , Gryzlak, Brian , Rudzianski, Nicholas J, Serrano, Kimberly , Wehrheim, Abigayle M., Grewal, Udhayvir Singh , Halfdanarson, Thorvardur R, Gamblin, T Clark, Cowell, Lindsay G, Else, Tobias , Chandaka, Sravani , He, Fiona , Geller, David, Ramirez, Robert A, Lancaster, W. M., Mailman, Josh A, Moran, Heather, Wahmann, Maryann, Gellerman, Elyse, Chrischilles, E., Investigators, The NET-PRO Study, Chamberlain, Alanna M, Cerda, Vanessa, Early, Carol, Hamilton, Harley C, Indrees, Kamran, Lewis-Hughes, A., O’Dell, Angela L, Roller, Lance, Taylor, Bradley W, Tepper, Mia S, Wahmann, Maryann, West, Kristin M, Zamba, Gideon K D, O’Rorke, Michael A. , Xu, Tao , McDowell, Bradley D , Gryzlak, Brian M , Rudzianski, Nicholas J , Serrano, Kimberly C , Grewal, Udhayvir S , Dillon, Joseph S , Halfdanarson, Thorvardur R , Else, Tobias , Soares, Heloisa P , Sukrithan, Vineeth , Sanoff, Hanna , He, Fiona C , Ramirez, Robert A , Liu, Mei , Mailman, Josh , Moran, Heather , Wahmann, Maryann , Gellerman, Elyse , Chrischilles, Elizabeth A , Xu, Tao , Chandrasekharan, Chandrikha , Dillon, Joseph S. , Hálfdánarson, Þorvarður R. , Gamblin, T. Clark , Cowell, PhD Lindsay G., Soares, Heloisa P. , Sukrithan, Vineeth , Sanoff, Hanna K. , Liu, Mei , Lancaster, William, Mailman, Josh , Chamberlain, Alanna M. , Hourcade, Juan Pablo , Kazmi, Syed Mohammad Ali , Lancaster, William, Ramnaraign, Brian Hemendra , Taylor, Bradley , West, Kristin M, Zamba, Gideon K D

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 3, 2026 | Volume: 118 | Issue: 8 | Pages: 1403-1415

10.1093/jnci/djag069 | PMID 41808486 Get It

Abstract Background Neuroendocrine tumors (NETs) are rare, heterogeneous neoplasms associated with prolonged survival and substantial symptom burden. However, patient-reported outcomes across NET subtypes remain poorly characterized, particularly in real-world settings. This study describes baseline health-related quality of life (HRQoL) and care experiences among patients with gastroenteropancreatic and lung NETs, examining differences by tumor site and time since diagnosis. Methods The Neuroendocrine Tumors–Patient Reported Outcomes study is a prospective, multi-institutional US cohort of adults (aged 18 years and older) with incident small intestinal, pancreatic, gastroenteropancreatic, or lung NETs diagnosed from January 2018 through September 2024, identified via a validated electronic medical record–based computable phenotype. Baseline surveys assessed HRQoL, symptoms, care experiences, and clinical characteristics using validated instruments. Descriptive statistics and standardized mean differences compared responses by NET site and time since diagnosis. Results Among 2367 participants (mean age = 57.8 years; 57.3% female), 1974 had gastroenteropancreatic NETs (659 small intestinal NET, 555 pancreatic NET) and 393 had lung NETs. Fatigue (mean = 33.0), insomnia (mean = 32.5), and diarrhea (mean = 25.7) were the most burdensome symptoms. Lung NET patients reported worse dyspnea (standardized mean difference = 0.58, P < .001) and lower physical, role, and global QoL scores than those with gastroenteropancreatic NETs, while pancreatic NET patients reported better functioning. Diarrhea worsened over time, especially in small intestinal NETs. Most rated care highly (75.3%) but cited concerns about treatment side effects (80.4%), costs (60.7%), and travel burden (58.8%). Conclusions This large US cohort reveals persistent symptom burden and HRQoL variation by tumor site and disease duration, underscoring the need for longitudinal HRQoL assessment in NET care.
Using a participation monitoring database to enhance recruitment in a rare cancer population
O’Rorke, Michael A. , Gryzlak, Brian , Xu, Tao, DeCook, Rhonda, Rudzianski, Nicholas J., Serrano, Kimberly , Wehrheim, Abigayle M., Schnell, Michael J., Witter, Carrie L., Gamblin, T. Clark , Kazmi, Syed Sohail, Cowell, Lindsay G., Else, Tobias, Chandaka, Sravani , Sanoff, Hanna K. , He, Fiona , Ramirez, Robert A., Liu, Mei, Lancaster, William, Mailman, Josh , Moran, Heather, Wahmann, Maryann, Gellerman, Elyse, Chrischilles, Elizabeth A., Liu, Mei , Sanoff, Hanna , O’Rorke, Michael , McDowell, Bradley D. , Rudzianski, Nicholas J , Serrano, Kimberly C., Grewal, Udhayvir Singh , Chandrasekharan, Chandrikha , Dillon, Joseph S. , Hálfdánarson, Þorvarður R. , Cowell, PhD Lindsay G., Else, Tobias , Soares, Heloisa P. , Sukrithan, Vineeth , Geller, David A. , Ramirez, Robert A., Lancaster, William, Chrischilles, Elizabeth A.

Mayo Clinic

Journal of Clinical and Translational Science | February 13, 2026 | Volume: 10 | Issue: 1 | Pages: No page available

10.1017/cts.2026.10703 | PMID 41822553 Get It

Abstract Introduction: Recruitment for rare disease studies is challenging due to small eligible populations. Traditional clinical research management systems often lack tools to track recruitment contacts prior to enrollment. The NET-PRO study, focused on neuroendocrine tumors (NETs), implemented a participation monitoring system to enhance recruitment efficiency and representativeness. Methods: NET-PRO is a multicenter cohort study of 2538 adults diagnosed with gastroenteropancreatic (GEP) or lung NETs between January 2018 and September 2024. Recruitment occurred from January 2022 to February 2025 across 14 U.S. medical centers. Sites used flexible recruitment methods (email, mail, phone, in-clinic) and tracked contacts using REDCap-based tools. Participant characteristics were analyzed by enrollment mode (online or mail) and recruitment difficulty (number of contacts required prior to enrollment) using standardized mean differences, chi-square tests, and ANOVA. Results: Of 9279 contacted patients, 2675 consented (28.8%) and 2538 enrolled (27.4%). Most enrolled online (83.2%), while 16.8% enrolled by mail. Mail respondents were older, had lower education and income, and more comorbidities. Among those enrolled, recruitment difficulty was associated with older age, lower education and income, but not comorbidity. Over half of the most difficult-to-recruit participants enrolled online. Contact methods varied by attempt, with email dominating early contacts and phone/mail used more in later attempts. Conclusions: A participation monitoring tool supported flexible, multimodal recruitment and improved sample representativeness in a rare cancer study. Tracking recruitment contacts enabled adaptive strategies and may reduce bias in observational research by enabling better outreach to harder-to-reach populations.
Risankizumab for Ulcerative Colitis
Louis, Edouard, Panaccione, Remo, Biedermann, Luc , Colombel, Jean–Frédéric, D’Haens, Geert , Hisamatsu, Tadakazu , Siegmund, Britta , Boland, Brigid S. , Melmed, Gil , Armuzzi, Alessandro , Levine, Phillip, Kalabic, Jasmina , Cheng, Ling, Shu, Lei , Duan, W. Rachel, Pivorunas, Valerie , González, Yuri Sánchez , D’Cunha, Ronilda , Neimark, Ezequiel, Wallace, Kori, Ferrante, Marc , Group, INSPIRE and COMMAND Study, Balderramo, Domingo , Goncalves, Silvina A., Lasa, Juan, Novillo, Abel, Ruffinengo, Orlando, Heeren, Sonja, Reinisch, Walter , Baert, Filip , Colard, A, Ferrante, Marc, Franchimont, Denis , Rahier, Jean‐François , Francesconi, Carlos Fernando de Magalhães , Stanchev, Desislav , Atkinson, Kenneth, Beaton, Melanie, Greenbloom, Susan, Lachance, Jean-Rene, Lim, Allen, Samson, Jean-Michel, Shulman, Scott, Siffledeen, Jesse, Alfaro, Ignacio , Valenzuela, Carlos , Walsen, Gustavo, An, Ping , Cao, Qian , Chen, Yan , Gao, Xiang , Hou, Xiaohua , Hu, Naizhong, Liu, Mei , Lungen, LU, Ran, Zhihua, Tang, Tongyu , Yang, Shaoqi , Zhan, Qiang , Zhang, Guoxin , Zhang, Xiaolan , Zhong, Jie , Zou, Xiaoping, Álvarez, Eligio, Ricaurte, Juan, Borzan, Vladimir , Puljiz, Željko , Svoboda, Pavel , Ulbrych, Jan, Vaňásek, Tomáš , Ali, Ezzat, Salem, Osama , Sawah, Hisham, Altwegg, Romain , Flamant, Mathurin, Hébuterne, Xavier , Deppe, Herbert, Klaus, Jochen , Kucharzik, Torsten , Mertens, Jessica, Mroß, Michael, Reindl, Wolfgang , Schiefke, Ingolf, Schreiber, Stefan, Sturm, Andreas , Bamias, Georgios, Manolakopoulos, Spilios , Mantzaris, Gerassimos J. , Tzouvala, Maria , Viazis, N. , Avni‐Biron, Irit , Goldin, Eran , Katz, Lior H. , Lahat-Zok, Adi, Segal, Arik, Colecchia, Antonio , Cosintino, R. , Geccherle, Andrea, Monteleone, Giovanni , Privitera, Antonino Carlo , Vangeli, Marcello, Abe, Yasuhiko , Aoyama, Nobuo , Endo, Yutaka , Esaki, Motohiro, Fujii, Toshimitsu , Fukuda, Katsuyuki , Hirai, Fumihito , Hisanaga, Yasuhiro, Horiki, Noriyuki , Iguchi, Mikitaka , Ishiguro, Yoh , Ito, Hiroaki , Kamikozuru, Koji , Kato, Jun , Kawanishi, Teruki, Kobayashi, Taku , Kuge, Hiroyuki , Masuda, Tomoyuki, Matsuoka, Katsuyoshi , Matsushima, Kayoko , Matsushima, Masashi, Motoya, Satoshi , Nakai, Katsuhiko, Nakajima, Koichi, Nakamura, Masanao, Nishida, Atsushi , Nishikawa, Takahiro , Nishimata, Nobuaki, Ochiai, Toshiaki, Ohmiya, Naoki , Ohnishi, Yoshifumi , Oka, Shiro , Ozeki, Keiji , Saito, Daisuke, Saruta, Masayuki, Sasaki, Makoto, Shimizu, Masahito , Sujino, Tomohisa , Takatori, Hajime , Takatsu, Noritaka , Tokito, Satoki, Endo, Toshiyuki, Toyokawa, Tatsuya , Uenoyama, Yoshito , Yamamoto, Takatsugu, Yasuda, Hiroshi , Yokoyama, Kaoru , Jonaitis, Laimas, Kazėnaitė, Edita, Te, Lourdes Lol-be Pinzon, Lutgens, Maurice, Brooker, James, Griffiths, Ben, Inns, Stephen , Schultz, Michael, Eszyk, Jerzy, Kleczkowski, D, Kopoń, Adam, Petryka, Robert, Romańczyk, Tomasz , Rydzewska-Wyszkowska, Grażyna , Sikorski, Piotr, Talarek, Michał, Ministro, Paula , Tavares, Helena, Diculescu, Mihai-Mircea, Goldiș, Adrian , Agafina, Alina, Edin, Anton, Gerasimova, Evgenia, Gettueva, Maryana, Кашников, В. Н. , Pirmagomedov, Albert , Rafalskiy, Vladimir , Шарапова, К. М., Varganova, Daria L , Grgov, Saša, Svorcan, Petar , Tarabar, Dino, Ling, Khoon Lin , Baláž, Jozef, Ďurina, J, Greguš, Miloš, Laclav, Martin , Deetlefs, Eduan, Peter, Jonny , Rajabally, Muhammad, Rosa, Jennifer, Zyl, JI van, Wright, John , Jang, Byung Ik , Kang, Sang-Bum, Kim, Duk-Hwan , Kim, Tae Oh , Kim, Young-Ho , Song, Geun Am , Laria, Luisa Castro, Piudo, Ana Echarri, Ramirez, Vincent Hernandez, Martín‐Arranz, María Dolores , Trastoy, Pilar Varela, Mendoza, M Vera, Lördal, Mikael, Chang, Chung-Hsin, Kuo, Chia-Jung , Lin, Ching‐Pin , Tu, Chia–Hung, Erzın, Yusuf , Soykan, İrfan , Kravchenko, Tetiana , Tsarynna, Nataliia, Vyshyvanyuk, Vira , Cummings, Fraser , Kapur, Kapil , Kaser, Arthur , Kent, Alexandra , Parkes, Gareth, Patel, Kamal , Steel, Alan , Aberra, Faten , Aguilar, Humberto , Al‐Bawardy, Badr , Barnes, Matthew D., Beck, Kendall , Berkelhammer, Charles , Bullock, Jeff, Chiplunker, Adeeti , Dalal, Robin, Dalal, Sushila , Delgado, Belkis, DiGiovanna, Michael P., Duvall, George, Freedland, Curtis, Friedenberg, Keith, Gaidos, Jill , Ginsburg, Philip, Hassanein, Tarek , Higgins, Peter , Hou, Jason K. , Huilgol, Vivek, Inamdar, Nikhil, Kapur, Saurabh, Kerman, David H., Levine, Henry, Lodhia, Nilesh, Mayoral, Jaime L., McNeil, Donald, Mushahwar, Andria M., Ojeas, Harry, Patel, Bhaktasharan, Phillips, Raymond E. , Pouzar, Joe, Sarles, H, Schock, Joel, Sedghi, Shahriar , Shah, Nirav V. , Stokesberry, David, Su, Le‐Chu, Verma, Dharmendra, Weber, John T. , Younes, Ziad , Zisman, Timothy L. , Melmed, Gil Y , Kobayashi, Taku , Siegmund, Britta , Schreiber, Stefan , Bossuyt, Peter , Parkes, Gareth, Peyrin‐Biroulet, Laurent , Wu, Kaichun , Chen, Su , Atreya, Raja Narayana , Loftus, Edward V. , Group, INSPIRE and COMMAND Study, Reinisch, Walter , Dewit, Olivier , Franchimont, Denis , Kaiser, Roberto Luiz , Parra, Rogério Serafim , Sassaki, Lígia Yukie , Пенчев, Пламен , Bessissow, Talat , Lachance, Jean-René, Panaccione, Remo , Walsen, Gustavo, Chen, Youxiang , Li, Yan , Liu, Fei , Wang, Xin , Zhan, Qiang, Zhang, Hu , Zhang, Jie , Ricaurte, Juan, Krznarić, Željko , Bortlík, Martin , Svoboda, Pavel, Kjeldsen, Jens , Munck, Lars Kristian , Poulsen, Anja, Waked, Imam A. , Fumery, Mathurin , Laharie, David , Roblin, Xavier , Tréton, Xavier , Deppe, Herbert, Hasselblatt, Peter , Kandulski, Arne , Krause, Thomas , Naumann, Axel, Schreiber, Stefan , Schubert, Stefan, Κoutroubakis, Ioannis E. , Ardizzone, Sandro , Cicala, Michele , Gasbarrini, Antonio , Giannini, Edoardo Giovanni , Gionchetti, Paolo , Luzza, Francesco , Saibeni, Simone , Abe, Yasuhiko, Asonuma, Kunio , Hisanaga, Yasuhiro, Ishigami, Keisuke, Kakuta, Yoichi , Maemoto, Atsuo , Nakajima, Koichi, Nishida, Atsushi, Sasaki, Makoto, Sugimoto, Ken , Suzuki, Takayoshi , Takedatsu, Hidetoshi , Takeuchi, Ken, Tanaka, Hiroki , Tokito, Satoki, Yamamoto, Takayuki , Derovs, Aleksejs , Puķītis, Aldis , Jonaitis, Laimas Virginijus , Gearry, Richard B. , Griffiths, Ben, Kierkuś, Jarosław , Reguła, Jarosław , Cerqueira, Rute Maria , Goncalves, Tiago, Lopes, Susana , Portela, Francisco , Seicean, Andrada , Gerasimova, Evgenia, Sharapova, Ksenia, Smolyarchuk, Е. А. , Jovanović, Igor , Balaz, Jozef, Drobne, David , Wright, John, Cheon, Jae Hee , Kim, Jee Hyun , Lee, Jong Hun , Lee, Kang‐Moon , Park, Dong Il , Argüelles‐Arias, Federico , Piudo, Ana Echarri, García‐López, Santiago , Ramirez, V Hernández, Misselwitz, Benjamin , Chou, Jen‐Wei , Tu, Chia‐Hung , Alkım, Hüseyin , Kravchenko, Tetiana, Ahmad, Tariq, Parkes, Gareth, Speight, Richard, Ananthakrishnan, Ashwin N. , Barnes, Matthew, Bullock, Jeff, DiGiovanna, Michael, Hong, John D. , Huilgol, V.R., Phillips, Raymond, Siddiqui, Junaid, Swaminath, Arun C. , Weber, John, Matsuoka, K

Mayo Clinic

JAMA | July 22, 2024 | Volume: 332 | Issue: 11 | Pages: 881

10.1001/jama.2024.12414 | PMID 39037800 Get It

Importance The clinical effects of risankizumab (a monoclonal antibody that selectively targets the p19 subunit of IL-23) for the treatment of ulcerative colitis are unknown. Objective To evaluate the efficacy and safety of risankizumab when administered as an induction and a maintenance therapy for patients with ulcerative colitis. Design, Setting, and Participants Two phase 3 randomized clinical trials were conducted. The induction trial was conducted at 261 clinical centers (in 41 countries) and enrolled 977 patients from November 5, 2020, to August 4, 2022 (final follow-up on May 16, 2023). The maintenance trial was conducted at 238 clinical centers (in 37 countries) and enrolled 754 patients from August 28, 2018, to March 30, 2022 (final follow-up on April 11, 2023). Eligible patients had moderately to severely active ulcerative colitis; a history of intolerance or inadequate response to 1 or more conventional therapies, advanced therapies, or both types of therapies; and no prior exposure to risankizumab. Interventions For the induction trial, patients were randomized 2:1 to receive 1200 mg of risankizumab or placebo administered intravenously at weeks 0, 4, and 8. For the maintenance trial, patients with a clinical response (determined using the adapted Mayo score) after intravenous treatment with risankizumab were randomized 1:1:1 to receive subcutaneous treatment with 180 mg or 360 mg of risankizumab or placebo (no longer receiving risankizumab) every 8 weeks for 52 weeks. Main Outcomes and Measures The primary outcome was clinical remission (stool frequency score ≤1 and not greater than baseline, rectal bleeding score of 0, and endoscopic subscore ≤1 without friability) at week 12 for the induction trial and at week 52 for the maintenance trial. Results Among the 975 patients analyzed in the induction trial (aged 42.1 [SD, 13.8] years; 586/973 [60.1%] were male; and 677 [69.6%] were White), the clinical remission rates at week 12 were 132/650 (20.3%) for 1200 mg of risankizumab and 20/325 (6.2%) for placebo (adjusted between-group difference, 14.0% [95% CI, 10.0%-18.0%], P < .001). Among the 548 patients analyzed in the maintenance trial (aged 40.9 [SD, 14.0] years; 313 [57.1%] were male; and 407 [74.3%] were White), the clinical remission rates at week 52 were 72/179 (40.2%) for 180 mg of risankizumab, 70/186 (37.6%) for 360 mg of risankizumab, and 46/183 (25.1%) for placebo (adjusted between-group difference for 180 mg of risankizumab vs placebo, 16.3% [97.5% CI, 6.1%-26.6%], P < .001; adjusted between-group difference for 360 mg of risankizumab vs placebo, 14.2% [97.5% CI, 4.0%-24.5%], P = .002). No new safety risks were detected in the treatment groups. Conclusion and Relevance Compared with placebo, risankizumab improved clinical remission rates in an induction trial and in a maintenance trial for patients with moderately to severely active ulcerative colitis. Further study is needed to identify benefits beyond the 52-week follow-up. Trial Registration ClinicalTrials.gov Identifiers: NCT03398148 and NCT03398135
Polyglutamine (CAG) Intermediate Repeat Expansions in ATXN2 is Associated with a More Aggressive Form of ALS Across Multiple Independent Cohorts (2094)
Hurt, Jessica A. , Wuu, Joanne , Ford, Alice F., Elman, Lauren , McCluskey, Leo, Liu, Mei , Chang, Ih , Rademakers, Rosa , Benatar, Michael, Harms, Matthew, Currier, Nicolas , McMillan, Corey T. , Tsai, Ellen A. , Deerlin, Vivianna M. Van , Quinn, Colin , Liu, Mei, Blitterswijk, Marka van , Sun, Chao , Harms, Matthew B.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.2094 Get It

An open natural language processing (NLP) framework for EHR-based clinical research: a case demonstration using the National COVID Cohort Collaborative (N3C)
Liu, Sijia , Wen, Andrew , Wang, Liwei , Fu, Sunyang , Miller, Robert , Williams, Andrew E. , Harris, Daniel R. , Liu, Mei , Abu-el-rub, Noor , Schutte, Dalton, Zhang, Rui , Osborne, John D. , He, Yongqun , Topaloĝlu, Ümit , Hong, Stephanie , Schaffter, Thomas , Fuentes, Rafael , Xu, Hua , He, Huan , Fu, Sunyang , Williams, Andrew , Harris, Daniel , Kavuluru, Ramakanth , Liu, Mei , Zhang, Rui , Rouhizadeh, Masoud , Osborne, John D , He, Yongqun , Topaloglu, Umit , Saltz, Joel H , Schaffter, Thomas , Pfaff, Emily , Chute, Christopher G , Haendel, Melissa , Szolovits, Peter , Xu, Hua , Liu, Hongfang , Liu, Sijia , Wen, Andrew , Abu-El-Rub, Noor , He, Huan , Saltz, Joel , Chute, Christopher G. , Duong, Timothy Q. , Haendel, Melissa , Liu, Hongfang

Mayo Clinic

Journal of the American Medical Informatics Association | August 8, 2023 | Volume: 30 | Issue: 12 | Pages: 2036-2040

10.1093/jamia/ocad134 | PMID 37555837 Get It

Abstract Despite recent methodology advancements in clinical natural language processing (NLP), the adoption of clinical NLP models within the translational research community remains hindered by process heterogeneity and human factor variations. Concurrently, these factors also dramatically increase the difficulty in developing NLP models in multi-site settings, which is necessary for algorithm robustness and generalizability. Here, we reported on our experience developing an NLP solution for Coronavirus Disease 2019 (COVID-19) signs and symptom extraction in an open NLP framework from a subset of sites participating in the National COVID Cohort (N3C). We then empirically highlight the benefits of multi-site data for both symbolic and statistical methods, as well as highlight the need for federated annotation and evaluation to resolve several pitfalls encountered in the course of these efforts.
Seasonal variation in blood pressure control across US health systems
Nilles, Ester Kim , Champon, XiaoXia, Mulder, Hillary, Shaw, Kathryn M., Smith, Myra, Lampron, Zachary, Viera, Anthony J. , Chuang, Cynthia H. , McTigue, Kathleen M. , McClay, James C. , Maeztu, Carlos , Sanders, Margaret , Warren, Nate, VanWormer, Jeffrey J. , Modrow, Madelaine Faulkner , Pletcher, Mark J. , O’Brien, Emily C. , Mulder, Hillary , Pletcher, Mark J , Mulder, Hillary , Faulkner Modrow, Madelaine , Wozniak, Gregory , Chamberlain, Alanna M. , Carton, Thomas W. , Ahmad, Faraz S. , Steinberg, Benjamin A. , Polonsky, Tamar S. , Singh, Rajbir , Liu, Mei , Park, Soohyung , Rakotz, Michael , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

Journal of Hypertension | March 8, 2023 | Volume: 41 | Issue: 5 | Pages: 751-758

10.1097/hjh.0000000000003396 | PMID 36883471 Get It

Objective: We aimed to characterize seasonal variation in US population-based blood pressure (BP) control and BP-related metrics and evaluate the association between outdoor temperature and BP control variation. Methods: We queried electronic health records (EHRs) from 26 health systems, representing 21 states, to summarize BP metrics by quarters of 12-month periods from January 2017 to March 2020. Patients with at least one ambulatory visit during the measurement period and a hypertension diagnosis during the first 6 months or prior to the measurement period were included. Changes in BP control, BP improvement, medication intensification, average SBP reduction after medication intensification across quarters and association with outdoor temperature were analyzed using weighted generalized linear models with repeated measures. Results: Among 1 818 041 people with hypertension, the majority were more than 65 years of age (52.2%), female (52.1%), white non-Hispanic (69.8%) and had stage 1/2 hypertension (64.8%). Overall, BP control and process metrics were highest in quarters 2 and 3, and lowest in quarters 1 and 4. Quarter 2 had the highest percentage of improved BP (31.95 ± 0.90%) and average SBP reduction after medication intensification (16 ± 0.23 mmHg). Quarter 3 had the highest percentage of BP controlled (62.25 ± 2.55%) and lowest with medication intensification (9.73 ± 0.60%). Results were largely consistent in adjusted models. Average temperature was associated with BP control metrics in unadjusted models, but associations were attenuated following adjustment. Conclusion: In this large, national, EHR-based study, BP control and BP-related process metrics improved during spring/summer months, but outdoor temperature was not associated with performance following adjustment for potential confounders.
PBX1-SIRT1 positive feedback loop attenuates ROS-mediated HF- MSC senescence and apoptosis
Wang, Yuan , Sui, Yutong , Niu, Ye, Liu, Dan , Xu, Qi , Liu, Feilin , Zuo, Kuiyang , Liu, mingsheng, Sun, Wei , Liu, Zinan , Zou, Fei , Shi, Jiahong , Liu, Xiao mei, Liu, Jinyu , Zuo, Kuiyang , Wang, Ziyu

Mayo Clinic

No container title available | April 15, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1545647/v1 Get It

Abstract Background: Stem cell senescence and depletion are major causes of organismal aging and aging-related diseases. The NAD–SIRT1–PARP1 axis has garnered remarkable interest owing to its significant role in regulating stem cell senescence and organismal aging. Event though our recent study showes that PBX1 overexpression attenuates hair follicle-derived mesenchymal stem cell (HF-MSC) senescence and apoptosis by regulating ROS-mediated DNA damage via downregulation of PARP1 expression, suggesting PARP1 downregulation is a common manifestation of the roles of both PBX1 and SIRT1 in the attenuation of HF-MSC senescence, and implying a potential link between PBX1 and SIRT1 via PARP1. Methods: HF-MSCs overexpressing PBX1, overexpressing both PBX1 and PARP1, downregulating SIRT1, and overexpressing PBX1 and downregulating SIRT1 were generated, and biomarkers related to cell senescence, apoptosis, DNA damage, and repair were detected at the cellular and protein levels. Results: (1) PBX1 overexpression alleviated HF-MSC senescence and apoptosis accompanied by upregulation of SIRT1 expression, downregulation of PARP1 expression, and increased intracellular NAD and ATP levels. (2) SIRT1 knockdown or PARP1 overexpression enhanced cellular senescence and apoptosis, accompanied by increased ROS accumulation and DNA damage aggravation and decreased intracellular NAD and ATP levels. (3) PBX1 overexpression rescued HF-MSC senescence and apoptosis induced by SIRT1 knockdown or PARP1 overexpression. (4) Dual luciferase reporter showed PBX1 enhanced SIRT1 expression by activating SIRT1 promoter. Conclusions: Our results reveal that a positive interaction feedback loop exists between PBX1 and SIRT1, that PBX1 is the upstream of SIRT1. To the best of our knowledge we are the first to report that there is a PBX1-SIRT1-PARP1 axis and this axis plays a critical role in alleviation of HF-MSC senescence and apoptosis. The results provide a new perspective on the mechanism of stem cell senescence and age-related disease prevention and treatment.
LRRK2 p.Ile1371Val Mutation in a Case with Neuropathologically Confirmed Multi-System Atrophy
Lee, Kelsey , Nguyen, Khanh-Dung H., Liu, Mei , Zafar, Faria , Saetern, Jimmy, Flierl, Adrian , Tetrud, James W., Langston, J. William, Schüle, Birgitt , Sun, Chao , Dickson, Dennis W.

Mayo Clinic

Journal of Parkinson’s Disease | February 20, 2018 | Volume: 8 | Issue: 1 | Pages: 93-100

10.3233/jpd-171237 | PMID 29480226 Get It

Background: Mutations in the leucine rich repeat kinase 2 ( LRRK2) gene are among the most common genetic causes of Lewy body Parkinson’s disease (PD). However, LRRK2 mutations can also lead to a variety of pathological phenotypes other than typical PD, including relatively pure nigrostriatal cell loss without alpha-synuclein-positive Lewy bodies or Lewy neurites, progressive supranuclear palsy (PSP), and multiple system atrophy (MSA). The mechanisms behind this remarkable pleomorphic pathology are currently unclear. Objective: To genetically and pathologically characterize a case with a LRRK2, p.Ile1371Val rare variant and pathologically proven MSA. Methods: From the brain donation program at the Parkinson’s Institute and Clinical Center, we selected 26 brains with family history and a with clinicopathological diagnosis of PD ( n = 20), MSA ( n = 4), or PSP ( n = 2). We performed neuropathological evaluation, including alpha-synuclein and tau immunohistochemistry and sequenced 188 genes that have been reported as causative for or associated with neurodegenerative diseases. Results: We identified a known LRRK2, p.Ile1371Val genetic variant in a case with clinically diagnosed and pathologically proven MSA. Neuropathology revealed that the olivopontocerebellar system was more affected than the striatonigral system. Conclusions: Our data suggest that genetic variants in the LRRK2 gene can present clinically and neuropathologically as MSA. One other LRRK2 genetic variant ( LRRK2, p.Ile2020Thr) has been reported with a neuropathological diagnosis of MSA. Interestingly, the LRRK2 variant ( LRRK2, p.Ile1371Val) identified here has been reported previously in a postmortem case with Lewy body PD. Future studies are critical to discover the mechanisms leading to different neurodegenerative trajectories both in neuronal and glial cell populations.